PGNX : Summary for Progenics Pharmaceuticals Inc. - Yahoo Finance

U.S. Markets open in 3 hrs 11 mins

Progenics Pharmaceuticals, Inc. (PGNX)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
8.64-0.03 (-0.35%)
At close: 4:00 PM EST
People also watch:
NBIXARRYRIGLSGYPPTIE
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close8.67
Open0.00
Bid4.14 x 100
Ask0.00 x
Day's Range8.27 - 8.82
52 Week Range3.61 - 9.23
Volume991,550
Avg. Volume1,326,053
Market Cap605.24M
Beta3.63
PE Ratio (TTM)55.74
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Valeant (VRX) Ups Sales Force to Support Xifaxan/Relistor
    Zacks5 days ago

    Valeant (VRX) Ups Sales Force to Support Xifaxan/Relistor

    Valeant Pharmaceuticals International, Inc. (VRX) announced that it is expanding its sales force to reach primary care physicians.

  • Capital Cube12 days ago

    ETFs with exposure to Progenics Pharmaceuticals, Inc. : November 23, 2016

    Categories: ETFs Yahoo Finance Click here to see latest analysis ETFs with exposure to Progenics Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to PGNX-US. Comparing the performance and risk of Progenics Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Progenics Pharmaceuticals, Inc. :PGNX-US: Earnings Analysis: Q3, 2016 By the Numbers : November 21, 2016
    Capital Cube14 days ago

    Progenics Pharmaceuticals, Inc. :PGNX-US: Earnings Analysis: Q3, 2016 By the Numbers : November 21, 2016

    Categories: Yahoo Finance Get free summary analysis Progenics Pharmaceuticals, Inc. reports financial results for the quarter ended September 30, 2016. We analyze the earnings along side the following peers of Progenics Pharmaceuticals, Inc. – Seattle Genetics, Inc., Nektar Therapeutics, Sucampo Pharmaceuticals, Inc. Class A, Synergy Pharmaceuticals, Inc., Astrazeneca PLC Sponsored ADR, Johnson & Johnson and Ironwood Pharmaceuticals, Inc. ... Read more (Read more...)